| Literature DB >> 30740124 |
Fangjie Cao1, Christopher L Souders Ii1, Veronica Perez-Rodriguez1, Christopher J Martyniuk1.
Abstract
While a number of genetic mutations are associated with Parkinson's disease (PD), it is also widely acknowledged that the environment plays a significant role in the etiology of neurodegenerative diseases. Epidemiological evidence suggests that occupational exposure to pesticides (e.g., dieldrin, paraquat, rotenone, maneb, and ziram) is associated with a higher risk of developing PD in susceptible populations. Within dopaminergic neurons, environmental chemicals can have an array of adverse effects resulting in cell death, such as aberrant redox cycling and oxidative damage, mitochondrial dysfunction, unfolded protein response, ubiquitin-proteome system dysfunction, neuroinflammation, and metabolic disruption. More recently, our understanding of how pesticides affect cells of the central nervous system has been strengthened by computational biology. New insight has been gained about transcriptional and proteomic networks, and the metabolic pathways perturbed by pesticides. These networks and cell signaling pathways constitute potential therapeutic targets for intervention to slow or mitigate neurodegenerative diseases. Here we review the epidemiological evidence that supports a role for specific pesticides in the etiology of PD and identify molecular profiles amongst these pesticides that may contribute to the disease. Using the Comparative Toxicogenomics Database, these transcripts were compared to those regulated by the PD-associated neurotoxicant MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). While many transcripts are already established as those related to PD (alpha-synuclein, caspases, leucine rich repeat kinase 2, and parkin2), lesser studied targets have emerged as "pesticide/PD-associated transcripts" [e.g., phosphatidylinositol glycan anchor biosynthesis class C (Pigc), allograft inflammatory factor 1 (Aif1), TIMP metallopeptidase inhibitor 3, and DNA damage inducible transcript 4]. We also compared pesticide-regulated genes to a recent meta-analysis of genome-wide association studies in PD which revealed new genetic mutant alleles; the pesticides under review regulated the expression of many of these genes (e.g., ELOVL fatty acid elongase 7, ATPase H+ transporting V0 subunit a1, and bridging integrator 3). The significance is that these proteins may contribute to pesticide-related increases in PD risk. This review collates information on transcriptome responses to PD-associated pesticides to develop a mechanistic framework for quantifying PD risk with exposures.Entities:
Keywords: adverse outcome pathways; gene networks; mitochondria; neurodegeneration; pesticides
Year: 2019 PMID: 30740124 PMCID: PMC6355689 DOI: 10.3389/fgene.2018.00701
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Figure 1Structures for pesticides epidemiologically associated with Parkinson's disease.
Summary of select pesticides associated with Parkinson's disease.
| Dieldrin | Insecticide | An organochlorine pesticide that is highly persistent, showing high bioaccumulation potential in lipid rich tissues such as the brain. The primary mechanism of neurotoxicity is antagonism of the GABAA receptor, preventing influx of chloride into the neuron and leading to excitation and death due to a lack of neuronal inhibition. This pesticide was banned in many developed countries in the 1970s but remains detectable in some environmental samples, as well as animal and human tissues. |
| Paraquat | Herbicide | Non-selective herbicide which is readily absorbed by plants. Paraquat impairs photosynthetic complexes and disrupts cell membranes due to its high propensity for redox cycling. Paraquat can cross the blood brain barrier (BBB) in a non-destructive, Na+, dependent manner in animal models. Paraquat is imported into dopaminergic neurons via dopamine active transporters, a mechanism similar to the neurotoxin MPTP. Both paraquat and MPTP are similar in chemical structure. Paraquat poisoning also leads to pulmonary toxicity or “Paraquat lung”. |
| Rotenone | Insecticide | A selective, but non-specific insecticide widely used in home gardens. It induces toxicity by inhibiting Complex I in the electron transporting chain of the mitochondria, showing relatively high toxicity in the nervous system of animals. Neuronal tissue exposed to rotenone showed high oxidative damage and this can lead to a loss of dopamine neurons. |
| Maneb | Fungicide | Maneb is a manganese-containing ethylenebis-dithiocarbamate fungicide used as a pesticide on fruit and a variety of other crops. Epidemiological studies have indicated that exposure to maneb alone or co-exposure to other pesticides increase the risk of Parkinsonism-like syndrome. This chemical can inhibit oxidative respiration via complex III inhibition in cells. |
| Ziram | Fungicide | Similar to maneb, this pesticide is a dithiocarbamate but is a member of the dimethyl-dithiocarbamates (DMDC) family. Individuals exposed to both maneb and ziram showed a 3-fold increase in the risk to PD. Compared to maneb, much less is known about the mechanisms underlying this pesticide. |
Examples of clinical and epidemiological evidence supporting a link between pesticides under review and Parkinson's disease.
| Case-Control Study | Finland | 2010 | 101 PD cases, 349 matched controls | Interquartile range, 1.95 (1.26–3.02) | Weisskopf et al., |
| Case-Control Study | India | 2013 | 145 subjects in the age group of 50 to 85 years, 70 subjects diagnosed with PD were enrolled | 2.09 (1.41-3.11), | Chhillar et al., |
| Case-Control Study | Canada | 1990 | 57 PD cases reported from physicians in the area, 122 age-matched controls randomly selected from electoral rolls | 4 ca, 0 co Expose to paraquat | Hertzman et al., |
| Case-Control Study | Canada | 1994 | 127 PD cases reported from physicians in area; 245 Controls randomly chosen from electoral rolls; 121 Patients with cardiac disease (CD) | 1.25 (0.34, 4.63), Population 1.11 (0.32, 3.87), CD | Hertzman et al., |
| Case-Control Study | Germany | 1996 | 380 PD cases aged 65 or less; 379 Neighborhood controls | 1 ca, 0 co exposed to paraquat | Seidler et al., |
| Case-Control Study | Taiwan | 1997 | 376 regional controls, 120 PD cases, 240 controls from the same hospital | 3.22 (2.41, 4.31) exposed to paraquat, 6.44 (2.41, 17.2) 20+ years of use | Liou et al., |
| Case-Control Study | Finland | 1999 | 123 PD cases, 246 matched controls | 3 cases and 5 controls reported the use of paraquat | Kuopio et al., |
| Cohort Study | USA | 2001 | 310 subjects selected and examined neurologically | 0.8 (0.5, 1.3) with any paraquat exposure; 0.9 (0.4, 2.4) Highest tertile exposure; 0.7 (0.5, 1.9) highest acre-years | Engel et al., |
| Case-Control Study | USA | 2005 | 100 cases from a private neurology practice, 84 controls from that same practice | 3.2 (0.4, 31.6) | Firestone et al., |
| Cohort Study | USA | 2007 | 83 Prevalent cases, 78 incident, 79557 without PD | 1.8 (1.0, 3.4) in prevalent cases; 1.0 (0.5, 1.9) in incident cases | Kamel et al., |
| Case-Control Study | USA | 2008 | 250 cases, 388 controls | 1.67 (0.22, 12.76) | Dhillon et al., |
| Case-Control Study | France | 2009 | 224 cases, 557 matched controls from the French health insurance system for agricultural workers | 1.2 (0.7, 2.1) all men; 1.6 (0.7, 3.4) Men age 65+ | Elbaz et al., |
| Case-Control Study | USA | 2009 | 368 cases, 31 randomly selected controls | 1.26 (0.72, 2.20) well water, 1.15 (0.82, 1.62) Ambient alone, 1.19 (0.77, 1.82) ambient or well water | Gatto et al., |
| Case-Control Study | USA | 2009 | 368 Cases, 346 Controls | 1.01 (0.71, 1.42) paraquat alone, 1.75 (1.13, 2.73) paraquat+maneb | Costello et al., |
| Case-Control Study | USA | 2009 | 324 cases, 334 controls | 2.99 (0.88, 3.48) Maneb+paraquat in those with 1 susceptible allele. 4.53 (1.70, 12.09) maneb + paraquat in those with 2+ susceptible alleles | Ritz et al., |
| Case-Control Study | North America | 2009 | 519 cases, 511 controls | 2.80 (0.81, 9.72) | Tanner et al., |
| Case-Control Study | USA | 2011 | 110 cases, 358 controls | 2.5 (1.4, 4.7); 2.4 (1.0, 5.5) < median duration; 3.6 (1.6, 8.1) > median duration | Tanner et al., |
| Case-Control Study | USA | 2011 | 362 Cases from neurology practices, 341 controls from Medicare records and randomly selected | 1.26 (0.86, 1.86) paraquat alone; 1.82 (1.03, 321) paraquat + ziram; 3.09 (1.69, 5.64) paraquat + ziram + maneb | Wang et al., |
| Case-Control Study | USA | 2012 | 404 cases, 526 controls | 0.90 (0.14, 5.43) | Firestone et al., |
| Case-Control Study | USA | 2007 | 83 prevalent cases and 79,557 controls. | 1.7 (0.6–4.7) with past rotenone use. | Kamel et al., |
| Case-Control Study | USA | 2008 | 100 cases and 84 controls | 10.0 (2.9–34.3) with use of “organic pesticides such as rotenone” | Dhillon et al., |
| Case-Control Study | USA | 2008 | 319 cases and 296 relative and other controls | 5.93 (0.63–56.10) with Botanical insecticide class including rotenone | Hancock et al., |
| Case-Control Study | USA | 2009 | 519 cases and 511 controls | 0.82 (0.05–13.34) with past rotenone use. (No association with PD) | Tanner et al., |
| Case-Control Study | USA | 2011 | 110 PD cases and 358 controls | OR = 2.5; 95% CI, 1.3–4.7 with past exposure to rotenone | Tanner et al., |
| Case-Control Study | USA | 2015 | 69 cases and 237 controls | OR = 3.7 (1.7, 8.1), 3.8 (1.5, 9.6), 5.5 (2.0, 15.3) with exposure to rotenone ( | Furlong et al., |
| Cohort Study | France | 2017 | 181,842 agricultural workers (4916 exposed to Rotenone) | 1.57 (1.08, 2.29), with past exposure to rotenone | Pouchieu et al., |
| Case Study | Brazil | 1988 | Two men of PD case | Two men presented parkinsonian syndromes and parkinsonian syndromes, moreover, significantly higher prevalence of parkinsonian syndromes were observed in fifty male rural workers with occupational exposure to maneb | Ferraz et al., |
| Case Study | Italy | 1994 | One man PD case | A man was exposed to maneb at 35-37-old age, a mild tremor associated with paresthesia appeared in his right leg and later spread to the ipsilateral arm, moreover, these symptoms then remained stable for about seven years. | Meco et al., |
| Case-Control Study | USA | 2009 | 324 incident PD patients, 334 controls | 2.99 (0.88, 3.48) in those with 1 susceptible allele 4.53 (1.70, 12.09) in those with 2 + susceptible alleles | Ritz et al., |
| Case-Control Study | USA | 2009 | 368 incident PD cases, 341 controls | 1.75 (1.13, 2.73) | Costello et al., |
| Case-Control Study | USA | 2011 | 362 Cases from neurology practices; 341 controls from Medicare records | 3.09 (1.69, 5.64) when exposed to paraquat + ziram + maneb | Wang et al., |
| Case-Control Study | USA | 2014 | 953 cases and 816 controls | 1.59 (0.92–2.67) at residence only, 1.92 (1.06–3.10) at workplace only, and 5.07 (1.58–12.6) at both conditions | Fitzmaurice et al., |
| Case-Control Study | Netherlands | 2017 | 202 PD cases and 362 hospital-based controls | 0.97 (0.72–1.30) | Brouwer et al., |
| Case-Control Study | USA | 2011 | 362 Cases from neurology practices; 341 controls from Medicare records | 1.82 (1.03, 321) paraquat + ziram; 3.09 (1.69, 5.64) paraquat + ziram + maneb; 5.98 (1.95, 18.32) in younger onset patients that were exposed to a combination of ziram and paraquat | Wang et al., |
| Case-Control Study | USA | 2013 | 360 PD cases and 816 population-based controls | 3.30 (1.50, 7.26) when exposed to ziram at both residence and workplace | Rhodes et al., |
| Case-Control Study | USA | 2014 | 953 cases and 816 controls | 3.33 (1.62, 6.88) when exposed to ziram at both residence and workplace | Fitzmaurice et al., |
Examples of pesticides associated with Parkinson's disease (MESH: D010300), based upon expression data from chemicals in the Comparative Toxicogenomics Database (CTD).
| A) | Rotenone | D012402 | 83-79-4 | Parkinson Disease | MESH:D010300 | 50.1 | 89 | 5 |
| Paraquat | D010269 | 4685-14-7 | Parkinson Disease | MESH:D010300 | 39.36 | 89 | 9 | |
| Maneb | D008344 | 12427-38-2 | Parkinson Disease | MESH:D010300 | 32.58 | 53 | 11 | |
| Dieldrin | D004026 | 60-57-1 | Parkinson Disease | MESH:D010300 | 15.43 | 48 | 30 | |
| B) | Permethrin | D026023 | 52645-53-1 | Parkinson Disease | MESH:D010300 | 32.77 | 50 | 10 |
| Chlorpyrifos | D004390 | 2921-88-2 | Parkinson Disease | MESH:D010300 | 29.48 | 57 | 15 | |
| Diazinon | D003976 | 333-41-5 | Parkinson Disease | MESH:D010300 | 26.13 | 44 | 17 | |
| Ditiocarb | D004050 | 147-84-2 | Parkinson Disease | MESH:D010300 | 24.51 | 43 | 18 | |
| Ziram | D015039 | 137-30-4 | Parkinson Disease | MESH:D010300 | 7.22 | 30 | 45 |
Provided in the table are the Chemical Name, ID and CAS number (if available), as well as the inference score and reference count that supports the relationship. A CAS Registry Number is a unique numerical identifier assigned by Chemical Abstracts Service (CAS). Data was accessed July 2018. (A) Pesticides and their rankings highlighted in this review and (B) Other examples of pesticides that are associated to transcriptome profiles generated in PD studies.
Lists of genes regulated by dieldrin, paraquat, rotenone, maneb, and ziram were downloaded from the Comparative Toxicogenomics Database, and compared amongst each other and to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) which converted to MPP+, causes clinical signs related to Parkinson's disease.
| ACHE | ENSG00000087085 | acetylcholinesterase (Cartwright blood group) [Source:HGNC Symbol;Acc:HGNC:108] |
| AIF1 | ENSG00000204472 | allograft inflammatory factor 1 [Source:HGNC Symbol;Acc:HGNC:352] |
| AKT1 | ENSG00000142208 | AKT serine/threonine kinase 1 [Source:HGNC Symbol;Acc:HGNC:391] |
| ALB | ENSG00000163631 | albumin [Source:HGNC Symbol;Acc:HGNC:399] |
| APAF1 | ENSG00000120868 | apoptotic peptidase activating factor 1 [Source:HGNC Symbol;Acc:HGNC:576] |
| BAD | ENSG00000002330 | BCL2 associated agonist of cell death [Source:HGNC Symbol;Acc:HGNC:936] |
| BAK1 | ENSG00000030110 | BCL2 antagonist/killer 1 [Source:HGNC Symbol;Acc:HGNC:949] |
| BAX | ENSG00000087088 | BCL2 associated X, apoptosis regulator [Source:HGNC Symbol;Acc:HGNC:959] |
| BCL2 | ENSG00000171791 | BCL2, apoptosis regulator [Source:HGNC Symbol;Acc:HGNC:990] |
| BCL2L1 | ENSG00000171552 | BCL2 like 1 [Source:HGNC Symbol;Acc:HGNC:992] |
| BDNF | ENSG00000176697 | brain derived neurotrophic factor [Source:HGNC Symbol;Acc:HGNC:1033] |
| BID | ENSG00000015475 | BH3 interacting domain death agonist [Source:HGNC Symbol;Acc:HGNC:1050] |
| BNIP3 | ENSG00000176171 | BCL2 interacting protein 3 [Source:HGNC Symbol;Acc:HGNC:1084] |
| CASP1 | ENSG00000137752 | caspase 1 [Source:HGNC Symbol;Acc:HGNC:1499] |
| CASP12 | ENSG00000204403 | caspase 12 (gene/pseudogene) [Source:HGNC Symbol;Acc:HGNC:19004] |
| CASP3 | ENSG00000164305 | caspase 3 [Source:HGNC Symbol;Acc:HGNC:1504] |
| CASP7 | ENSG00000165806 | caspase 7 [Source:HGNC Symbol;Acc:HGNC:1508] |
| CASP8 | ENSG00000064012 | caspase 8 [Source:HGNC Symbol;Acc:HGNC:1509] |
| CASP9 | ENSG00000132906 | caspase 9 [Source:HGNC Symbol;Acc:HGNC:1511] |
| CAT | ENSG00000121691 | catalase [Source:HGNC Symbol;Acc:HGNC:1516] |
| CCL2 | ENSG00000108691 | C-C motif chemokine ligand 2 [Source:HGNC Symbol;Acc:HGNC:10618] |
| CCND1 | ENSG00000110092 | cyclin D1 [Source:HGNC Symbol;Acc:HGNC:1582] |
| CDKN1A | ENSG00000124762 | cyclin dependent kinase inhibitor 1A [Source:HGNC Symbol;Acc:HGNC:1784] |
| COX5A | ENSG00000178741 | cytochrome c oxidase subunit 5A [Source:HGNC Symbol;Acc:HGNC:2267] |
| COX7A2L | ENSG00000115944 | cytochrome c oxidase subunit 7A2 like [Source:HGNC Symbol;Acc:HGNC:2289] |
| CREB1 | ENSG00000118260 | cAMP responsive element binding protein 1 [Source:HGNC Symbol;Acc:HGNC:2345] |
| CTSB | ENSG00000164733 | cathepsin B [Source:HGNC Symbol;Acc:HGNC:2527] |
| CYC1 | ENSG00000179091 | cytochrome c1 [Source:HGNC Symbol;Acc:HGNC:2579] |
| CYCS | ENSG00000172115 | cytochrome c, somatic [Source:HGNC Symbol;Acc:HGNC:19986] |
| CYP1A1 | ENSG00000140465 | cytochrome P450 family 1 subfamily A member 1 [Source:HGNC Symbol;Acc:HGNC:2595] |
| DDIT3 | ENSG00000175197 | DNA damage inducible transcript 3 [Source:HGNC Symbol;Acc:HGNC:2726] |
| DDIT4 | ENSG00000168209 | DNA damage inducible transcript 4 [Source:HGNC Symbol;Acc:HGNC:24944] |
| DRD2 | ENSG00000149295 | dopamine receptor D2 [Source:HGNC Symbol;Acc:HGNC:3023] |
| E2F1 | ENSG00000101412 | E2F transcription factor 1 [Source:HGNC Symbol;Acc:HGNC:3113] |
| ENO1 | ENSG00000074800 | enolase 1 [Source:HGNC Symbol;Acc:HGNC:3350] |
| ENO2 | ENSG00000111674 | enolase 2 [Source:HGNC Symbol;Acc:HGNC:3353] |
| FOS | ENSG00000170345 | Fos proto-oncogene, AP-1 transcription factor subunit [Source:HGNC Symbol;Acc:HGNC:3796] |
| GAPDH | ENSG00000111640 | glyceraldehyde-3-phosphate dehydrogenase [Source:HGNC Symbol;Acc:HGNC:4141] |
| GCLC | ENSG00000001084 | glutamate-cysteine ligase catalytic subunit [Source:HGNC Symbol;Acc:HGNC:4311] |
| GFAP | ENSG00000131095 | glial fibrillary acidic protein [Source:HGNC Symbol;Acc:HGNC:4235] |
| GPT | ENSG00000167701 | glutamic–pyruvic transaminase [Source:HGNC Symbol;Acc:HGNC:4552] |
| GPX1 | ENSG00000233276 | glutathione peroxidase 1 [Source:HGNC Symbol;Acc:HGNC:4553] |
| GPX4 | ENSG00000167468 | glutathione peroxidase 4 [Source:HGNC Symbol;Acc:HGNC:4556] |
| GSK3B | ENSG00000082701 | glycogen synthase kinase 3 beta [Source:HGNC Symbol;Acc:HGNC:4617] |
| GSTA4 | ENSG00000170899 | glutathione S-transferase alpha 4 [Source:HGNC Symbol;Acc:HGNC:4629] |
| HBA1 | ENSG00000188536 | hemoglobin subunit alpha 2 [Source:HGNC Symbol;Acc:HGNC:4824] |
| HBA1 | ENSG00000206172 | hemoglobin subunit alpha 1 [Source:HGNC Symbol;Acc:HGNC:4823] |
| HMOX1 | ENSG00000100292 | heme oxygenase 1 [Source:HGNC Symbol;Acc:HGNC:5013] |
| HSPA5 | ENSG00000044574 | heat shock protein family A (Hsp70) member 5 [Source:HGNC Symbol;Acc:HGNC:5238] |
| IDH3A | ENSG00000166411 | isocitrate dehydrogenase 3 (NAD(+)) alpha [Source:HGNC Symbol;Acc:HGNC:5384] |
| IFNG | ENSG00000111537 | interferon gamma [Source:HGNC Symbol;Acc:HGNC:5438] |
| IGF1 | ENSG00000017427 | insulin like growth factor 1 [Source:HGNC Symbol;Acc:HGNC:5464] |
| IL1B | ENSG00000125538 | interleukin 1 beta [Source:HGNC Symbol;Acc:HGNC:5992] |
| IL6 | ENSG00000136244 | interleukin 6 [Source:HGNC Symbol;Acc:HGNC:6018] |
| KIF1B | ENSG00000054523 | kinesin family member 1B [Source:HGNC Symbol;Acc:HGNC:16636] |
| LRRK2 | ENSG00000188906 | leucine rich repeat kinase 2 [Source:HGNC Symbol;Acc:HGNC:18618] |
| MAP2K1 | ENSG00000169032 | mitogen-activated protein kinase kinase 1 [Source:HGNC Symbol;Acc:HGNC:6840] |
| MAPK1 | ENSG00000100030 | mitogen-activated protein kinase 1 [Source:HGNC Symbol;Acc:HGNC:6871] |
| MAPK3 | ENSG00000102882 | mitogen-activated protein kinase 3 [Source:HGNC Symbol;Acc:HGNC:6877] |
| MAPT | ENSG00000186868 | microtubule associated protein tau [Source:HGNC Symbol;Acc:HGNC:6893] |
| MTOR | ENSG00000198793 | mechanistic target of rapamycin kinase [Source:HGNC Symbol;Acc:HGNC:3942] |
| MYC | ENSG00000136997 | MYC proto-oncogene, bHLH transcription factor [Source:HGNC Symbol;Acc:HGNC:7553] |
| NFE2L2 | ENSG00000116044 | nuclear factor, erythroid 2 like 2 [Source:HGNC Symbol;Acc:HGNC:7782] |
| NFKB1 | ENSG00000109320 | nuclear factor kappa B subunit 1 [Source:HGNC Symbol;Acc:HGNC:7794] |
| NOS2 | ENSG00000007171 | nitric oxide synthase 2 [Source:HGNC Symbol;Acc:HGNC:7873] |
| NTRK2 | ENSG00000148053 | neurotrophic receptor tyrosine kinase 2 [Source:HGNC Symbol;Acc:HGNC:8032] |
| ODC1 | ENSG00000115758 | ornithine decarboxylase 1 [Source:HGNC Symbol;Acc:HGNC:8109] |
| PARK2 | ENSG00000185345 | parkin RBR E3 ubiquitin protein ligase [Source:HGNC Symbol;Acc:HGNC:8607] |
| PIGC | ENSG00000135845 | phosphatidylinositol glycan anchor biosynthesis class C [Source:HGNC Symbol;Acc:HGNC:8960] |
| PRDX2 | ENSG00000167815 | peroxiredoxin 2 [Source:HGNC Symbol;Acc:HGNC:9353] |
| PRDX3 | ENSG00000165672 | peroxiredoxin 3 [Source:HGNC Symbol;Acc:HGNC:9354] |
| PTGS2 | ENSG00000073756 | prostaglandin-endoperoxide synthase 2 [Source:HGNC Symbol;Acc:HGNC:9605] |
| RELA | ENSG00000173039 | RELA proto-oncogene, NF-kB subunit [Source:HGNC Symbol;Acc:HGNC:9955] |
| SLC18A2 | ENSG00000165646 | solute carrier family 18 member A2 [Source:HGNC Symbol;Acc:HGNC:10935] |
| SLC6A3 | ENSG00000142319 | solute carrier family 6 member 3 [Source:HGNC Symbol;Acc:HGNC:11049] |
| SNCA | ENSG00000145335 | synuclein alpha [Source:HGNC Symbol;Acc:HGNC:11138] |
| SOD1 | ENSG00000142168 | superoxide dismutase 1 [Source:HGNC Symbol;Acc:HGNC:11179] |
| SOD2 | ENSG00000112096 | superoxide dismutase 2 [Source:HGNC Symbol;Acc:HGNC:11180] |
| TGFB1 | ENSG00000105329 | transforming growth factor beta 1 [Source:HGNC Symbol;Acc:HGNC:11766] |
| TH | ENSG00000180176 | tyrosine hydroxylase [Source:HGNC Symbol;Acc:HGNC:11782] |
| TIMP3 | ENSG00000100234 | TIMP metallopeptidase inhibitor 3 [Source:HGNC Symbol;Acc:HGNC:11822] |
| TJP1 | ENSG00000104067 | tight junction protein 1 [Source:HGNC Symbol;Acc:HGNC:11827] |
| TNF | ENSG00000232810 | tumor necrosis factor [Source:HGNC Symbol;Acc:HGNC:11892] |
| TP53 | ENSG00000141510 | tumor protein p53 [Source:HGNC Symbol;Acc:HGNC:11998] |
| TUBA1A | ENSG00000167552 | tubulin alpha 1a [Source:HGNC Symbol;Acc:HGNC:20766] |
| UCHL1 | ENSG00000154277 | ubiquitin C-terminal hydrolase L1 [Source:HGNC Symbol;Acc:HGNC:12513] |
| VEGFA | ENSG00000112715 | vascular endothelial growth factor A [Source:HGNC Symbol;Acc:HGNC:12680] |
The transcript had to be present in 4 out of the 6 gene lists to be included in the table below. These represent those transcripts that are most likely associated with pesticide-induced PD.
Figure 2Venn diagram comparing the number of transcripts that were associated with the pesticides under study and Parkinson's disease (PD) (from the Comparative Toxicogenomics Database). There were 10 transcripts that were altered by all four pesticides (rotenone, paraquat, maneb, and dieldrin).
Figure 3Pathway representation for dopamine metabolism. The darker the red color, the more frequent the association between the gene and the pesticides investigated. M, Maneb; P, Paraquat; R, Rotenone; D, Dieldrin; Z, Ziram.
Figure 4Transcripts that are regulated by pesticides associated with PD. These genes have also been identified in a meta-analysis and GWAS study (Chang et al., 2017) as those containing genetic mutations that are linked to PD. SNCA has been designated as being localized to the both the membrane and cytosol in this depiction, and is a major cytosolic protein but can interact with membranes.